Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma

References

• Kim SJ, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type. Int J Hematol. 2010;92:690–696.
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12:349–352.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, etet al. Frequent expression of P-glycoprotein/MDRl by nasal T-cell lymphoma cells. Cancer. 1995; 76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol. 2005;130:860–868.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99:1016–1020.
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Vinnikov D. L-asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017;17:759–768.
   PubMed Web of Science ®Google Scholar
• Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22:5223–5228.
   PubMed Web of Science ®Google Scholar
• NCCN. Non-Hodgkin’s Lymphomas; 2016.
   Google Scholar
• Broome J. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. J Exp Med. 1963;118:99–120.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;15:238–249.
   Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed. 2006;1:241–254.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114:794–799.
   PubMed Web of Science ®Google Scholar
• Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Futur Oncol. 2014;10:2615–2627.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004;24:1121–1125.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101:279–285.
   PubMed Web of Science ®Google Scholar
• Marini BL, Perissinotti AJ, Bixby DL, et al. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017;31:328–338.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study – Dana-Farber Cancer Institute ALL C. J Clin Oncol. 2013;31:1202–1210.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123:2026–2034.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–355.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117:1834–1839.
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665–1679.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91:24–31.
   PubMed Web of Science ®Google Scholar
• Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar(TM)) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110:379–384.
   PubMed Web of Science ®Google Scholar
• Pinheiro JPV, Mu HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar tm) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol. 2001;113:115–119.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Asselin BL, Koontz SE, et al. Clinical application of asparaginase activity levels following treatment with pegasparaginase. Pediatr Blood Cancer. 2015;62:1102–1105.
   PubMed Web of Science ®Google Scholar
• Benitez L, Perissinotti AJ, Santarossa M, et al. Letter to the editor: clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatr Blood Cancer. 2015;62:1115.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Lane AR, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children’s oncology group study AALL07P4. J Clin Oncol. 2014;32:3874–3882.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Blonquist TM, Hunt SK, et al. Randomized study of pegasparagase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL consortium protocol 11-001. In: Paper presented at 58th Annual Meeting of the American Society of Hematology; 2016. Available from: https://ash.confex.com/ash/2016/webprogram/Paper94488.html
   Google Scholar
• Park JH, Ritchie EK, Rao AV, et al. Pediatric-inspired regimen containing multiple doses of intravenous pegylated asparaginase appears safe and effective in newly diagnosed adult patients with Ph-negative acute lymphoblastic leukemia in adults up to Age 60: results of a multi-center phase I. In: Paper presented at 58th Annual Meeting of the American Society of Hematology; 2016. Available from: https://ash.confex.com/ash/2016/webprogram/Paper96465.html
   Google Scholar